Abstract
Plants are considered as an alternative system for a cost-effective production of recombinant biopharmaceuticals, the concept termed as molecular farming. While plant-based production systems have demonstrated success in producing viral vaccines, the application of plant systems to immune checkpoint inhibitors (ICIs) production is still in an earlier stage. The plant-derived ICIs have demonstrated efficacy in proof-of-concept studies; however, further research is essential to comprehensively assess their efficacy, safety, and potential for clinical application.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callSimilar Papers
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
